National Taiwan University

Animal Technology Institute Taiwan

Jang-Ming Lee

Pei-Wen Yang

Eric Chuang

Ching-Fu Tu

Kimiyoshi Tsuji

Chun-Jean Lee

Mong-Hsun Tsai

Shin-Kuang Chen

Max Ti-Kuang Hou

Pei-Chun Chen

Chuhsing K Hsiao

I-Jen Hsu

Yen-Ching Chen

Liang-Chuan Lai

The present invention provides an optical method for predicting treatment response, survival and recurrence of esophageal cancer patients, comprising analyzing the spectral signatures of patient's tumor tissue spectra. By the features of the present invention, the prediction result achieves the sensitivity of 75% and specificity of 73.3% in concurrent chemoradiotherapy (CCRT) response; the survival prediction rate achieves the sensitivity of 100%; the recurrence prediction rate achieves the sensitivity of 85.7%.

Optical method for predicting treatment response, survival and recurrence of esophageal cancer patients

The present invention relates to novel genetic markers associated with response of a patient with esophageal cancer (ECa) to chemoradiation therapy, and particularly to methods and kits for predicting an ECa patient's response to chemoradiation therapy by genotyping of the markers.

Biomarkers for predicting response of esophageal cancer patient to chemoradiotherapy

The invention provides a transgenic swine having a transgene encoding a human HLA-DQ or HLA-DR protein, and the swine cells thereof. The invention also provides a graft derived from the transgenic swine, in particular a graft-organ or a graft-tissue, which is useful for grafting into a human recipient.

Transgenic swine having HLA-D gene, swine cells thereof and xenografts therefrom

Growing community of inventors

Taipei, Taiwan

Jang-Ming Lee